Navigate Fool.com
Will LGND beat
the market?
Community Rating: 2 Stars: Unattractive

60.69 0.95 (1.59%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $60.62
Previous Close $59.74
Daily Range $58.70 - $61.04
52-Week Range $23.87 - $80.42
Market Cap $1.3B
P/E Ratio 138.93
Dividend (Yield) $0.00 (0.0%)
Volume 160,255
Average Daily Volume 350,362
Current FY EPS $1.11

How do you think LGND
will perform against the market?

Top LGND Bull/Bear Pitches


AllStarPortfolio (< 20)
Submitted February 18, 2010

zzlangerhans (99.58) wrote: Outperform on LGND with a limit of 1.6. Here's my pitch: Ligand Pharmaceuticals has a pipeline and business model that resembles a mid-to-large cap biotech but a … More

0 Replies Reply Report this Post

1337172979 (< 20)
Submitted September 19, 2010

Many people wonder why it has had such a dramatic downside in the last months given its promising pipeline, partnerships and already marketed products. At 1.56 and market cap under 200M it looks like … More

0 Replies Reply Report this Post

News & Commentary

2 Health Care Partnerships Go Head-To-Head

While the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end

Why Ligand Pharmaceuticals Inc. Shares Popped

Ligand shares soar after the company reports better than expected fourth-quarter results and provides its fiscal 2014 guidance. Can shares head even higher?

GlaxoSmithKline Gets FDA Nod for Promacta/Revolade

GlaxoSmithKline's treatment receives breakthrough therapy designation from the regulator.

Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today

Ligand Pharmaceuticals, ChemoCentryx, Medivation, and Teva could make health care headlines today. Here's why.

After Hours Most Active for Nov 27, 2013 : QQQ, LGND, ORCL, HD, MRO, TWTR, INTC, MSFT, RAD, CSCO, S

After Hours Most Active for Nov 27, 2013 : QQQ, LGND, ORCL, HD, MRO, TWTR, INTC, MSFT, RAD, CSCO, SIRI, GPS

The Simplest Biotech Growth Portfolio Ever

Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.

Stock Upgrades: Ball Corporation About to Bounce

Wall street ratings agencies set the tone for today's stock market.

Why Ligand Pharmaceuticals Shares Dipped

Ligand Pharmaceuticals demonstrates the profits and perils of being a royalty revenue company in the biotech sector.

Sector Update: Healthcare Flat Pre-Market; Aria up 10% as Sarissa Capital Discloses 6% Stake

Ligand Announces FDA Acceptance of Investigational New Drug Application for Glucagon Receptor Antago

See More LGND News...





Ligand Pharmaceuticals, Inc. (LGND) Description

Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases. Website: http://www.ligand.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks